Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Sep 06, 2023 (filed on Sep 06, 2023)Insider Name:Tomsche David ScottOwnership Type:Direct OwnershipSecurities:Common stock $0.10 per value per shareNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:3,100Price:$4.75
-
Jun 28, 2023 (filed on Aug 30, 2023)Insider Name:Gathagan Bryan K.Ownership Type:Direct OwnershipSecurities:Non-Qualified Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:$5.11
Filings by filing date
-
Sep 06, 2023 (filed on Sep 06, 2023)Insider Name:Tomsche David ScottOwnership Type:Direct OwnershipSecurities:Common stock $0.10 per value per shareNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:3,100Price:$4.75
-
Jun 28, 2023 (filed on Aug 30, 2023)Insider Name:Gathagan Bryan K.Ownership Type:Direct OwnershipSecurities:Non-Qualified Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:$5.11
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 56 Evergreen Drive PORTLAND ME 04103 |
Tel: | N/A |
Website: | https://immucell.com |
IR: | See website |
Key People | ||
Michael F. Brigham President, Chief Executive Officer, Treasurer, Secretary, Director | Bobbi Jo Brockmann Vice President - Sales and Marketing, Director | Elizabeth Luttrell Williams Vice President - Manufacturing Operations |
Business Overview |
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus). |
Financial Overview |
For the fiscal year ended 31 December 2023, ImmuCell Corp revenues decreased 6% to $17.5M. Net loss increased from $2.5M to $5.8M. Revenues reflect Unallocated segment decrease from $1K to $0K, United States segment decrease of 6% to $15.9M, Other segment decrease of 2% to $1.5M. Higher net loss reflects First Defense segment income decrease of 76% to $1.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.32 to -$0.75. |
Employees: | 79 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $50.52M as of Dec 31, 2023 |
Annual revenue (TTM): | $17.47M as of Dec 31, 2023 |
EBITDA (TTM): | -$3.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$5.77M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.57M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $10.99M as of Dec 31, 2023 |
Shares outstanding: | 7,750,864 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |